资讯
BioNexus Gene Lab Corp.与VITARRAY Global Pte. Ltd.签署战略外包协议。
KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp.(NASDAQ:BGLC, the "Company"))), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. ("MRNA Scientific"), has entered into a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. ("Vitarray"), an exempted private company incorporated in Singapore. This agreement focuses on the provision of mRNA dynamic gene detection services for the Southeast Asian market.
Under this agreement, MRNA Scientific will leverage its advanced medical testing facilities located in Kuala Lumpur, Malaysia, to provide outsourcing services for Vitarray's mRNA gene detection activities. This collaboration is aimed at enhancing the deployment of advanced molecular diagnostics throughout Southeast Asia, facilitating early disease detection and expanding access to innovative healthcare technologies.
Vitarray has been authorized by Huaxia Jingdu Renhe Medical Laboratory Co., Ltd. ("Huaxia"), a leading medical diagnostics company in China, to manage their overseas recruitment, promotion, and management of mRNA dynamic gene detection technology. This authorization provides Vitarray with the exclusive right to bring Huaxia's advanced gene detection technology to international markets, including Southeast Asia.
Key Terms of the Agreement:
1。 测试服务外包：
Vitarray将提供必要的样本和采血材料，而MRNA Scientific将提供试剂、实验室工作人员、耗材和检测设施。
2. 初步测试和合作：
双方将在开始长期合作之前进行一批初步的实验测试，以确保在质量和性能方面达成一致。
3. 成本降低与市场扩张：
通过这次合作伙伴关系，MRNA科学将大幅降低测试成本超过25%，使其服务更具盈利性。这种成本效益为mRNA动态基因检测服务的市场扩展提供了机会，同时提高了未来测试项目的利润空间。
4. 进一步合作：
该协议还为MRNA Scientific和Vitarray两家公司在技术和市场上加强合作奠定了基础，并计划在包括东南亚在内的各个市场推广mRNA动态基因检测技术的使用。
5. 保密和合规：
双方致力于对合作中涉及的所有技术、业务和医疗专家信息严格保密。
Under this agreement, MRNA Scientific will leverage its advanced medical testing facilities located in Kuala Lumpur, Malaysia, to provide outsourcing services for Vitarray's mRNA gene detection activities. This collaboration is aimed at enhancing the deployment of advanced molecular diagnostics throughout Southeast Asia, facilitating early disease detection and expanding access to innovative healthcare technologies.
Vitarray has been authorized by Huaxia Jingdu Renhe Medical Laboratory Co., Ltd. ("Huaxia"), a leading medical diagnostics company in China, to manage their overseas recruitment, promotion, and management of mRNA dynamic gene detection technology. This authorization provides Vitarray with the exclusive right to bring Huaxia's advanced gene detection technology to international markets, including Southeast Asia.
Key Terms of the Agreement:
1。 测试服务外包：
Vitarray将提供必要的样本和采血材料，而MRNA Scientific将提供试剂、实验室工作人员、耗材和检测设施。
2. 初步测试和合作：
双方将在开始长期合作之前进行一批初步的实验测试，以确保在质量和性能方面达成一致。
3. 成本降低与市场扩张：
通过这次合作伙伴关系，MRNA科学将大幅降低测试成本超过25%，使其服务更具盈利性。这种成本效益为mRNA动态基因检测服务的市场扩展提供了机会，同时提高了未来测试项目的利润空间。
4. 进一步合作：
该协议还为MRNA Scientific和Vitarray两家公司在技术和市场上加强合作奠定了基础，并计划在包括东南亚在内的各个市场推广mRNA动态基因检测技术的使用。
5. 保密和合规：
双方致力于对合作中涉及的所有技术、业务和医疗专家信息严格保密。
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
